Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavorixafor for G-CSF Dosage Reduction in Chronic Neutropenia
NCT07902830Phase 2Not yet recruiting
- Sponsor
- X4 Pharmaceuticals, Inc.
- Start
- Dec 2026
- Primary completion
- Jan 2029
01
Overview
Phase 2, open-label, single-arm trial of mavorixafor in neutropenia and Autoimmune neutropenia (AIN), sponsored by X4 Pharmaceuticals, Inc. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events, Percent Change in Average Daily G-CSF Dosage and 2 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
mavorixafor
03
Conditions
neutropeniaAutoimmune neutropenia (AIN)
Beyond the preview
Go deeper on NCT07902830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07902830.